nodes	percent_of_prediction	percent_of_DWPC	metapath
Arbutamine—Mirabegron—ALB—acquired immunodeficiency syndrome	0.201	0.54	CrCbGaD
Arbutamine—Epinephrine—TNF—acquired immunodeficiency syndrome	0.171	0.461	CrCbGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0236	0.0376	CbGpPWpGaD
Arbutamine—ADRB2—GPCRs, Other—ACKR1—acquired immunodeficiency syndrome	0.0223	0.0355	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.018	0.0286	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.0143	0.0228	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.014	0.0223	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.0137	0.0218	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.0129	0.0206	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.0109	0.0173	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0107	0.017	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.0104	0.0166	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00984	0.0157	CbGpPWpGaD
Arbutamine—ADRB3—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00932	0.0148	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00922	0.0147	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00883	0.0141	CbGpPWpGaD
Arbutamine—ADRB3—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00876	0.014	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00848	0.0135	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.00829	0.0132	CbGpPWpGaD
Arbutamine—ADRB2—GPCRs, Other—CCR5—acquired immunodeficiency syndrome	0.00802	0.0128	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00798	0.0127	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.00767	0.0122	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.0075	0.012	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.0075	0.012	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.0075	0.012	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00672	0.0107	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00646	0.0103	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00632	0.0101	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00608	0.00968	CbGpPWpGaD
Arbutamine—ADRB3—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.006	0.00956	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00584	0.0093	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00571	0.0091	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00571	0.0091	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.00571	0.0091	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00571	0.0091	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00558	0.00889	CbGpPWpGaD
Arbutamine—ADRB1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00553	0.00881	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00547	0.00871	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00544	0.00867	CbGpPWpGaD
Arbutamine—ADRB2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00541	0.00862	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00535	0.00852	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00524	0.00835	CbGpPWpGaD
Arbutamine—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.0052	0.00828	CbGpPWpGaD
Arbutamine—ADRB3—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00514	0.00819	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.00512	0.00816	CbGpPWpGaD
Arbutamine—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00509	0.0081	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00505	0.00804	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00474	0.00755	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.00463	0.00738	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00445	0.0071	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00445	0.0071	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00436	0.00694	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00436	0.00694	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00435	0.00693	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.00399	0.00635	CbGpPWpGaD
Arbutamine—ADRB3—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00392	0.00624	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.0039	0.00622	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00361	0.00575	CbGpPWpGaD
Arbutamine—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00356	0.00568	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00353	0.00562	CbGpPWpGaD
Arbutamine—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.00349	0.00555	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00345	0.00549	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00343	0.00547	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00339	0.0054	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00339	0.0054	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00339	0.0054	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.00332	0.00529	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.00332	0.00529	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.00331	0.00528	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00331	0.00528	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.0033	0.00525	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.0033	0.00525	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.00324	0.00516	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00323	0.00515	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00323	0.00514	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00323	0.00514	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00316	0.00503	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00312	0.00497	CbGpPWpGaD
Arbutamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00305	0.00486	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.003	0.00477	CbGpPWpGaD
Arbutamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.00299	0.00476	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00298	0.00475	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00293	0.00467	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00293	0.00467	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00293	0.00467	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00258	0.00411	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.00252	0.00402	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00246	0.00391	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00242	0.00386	CbGpPWpGaD
Arbutamine—ADRB1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00232	0.0037	CbGpPWpGaD
Arbutamine—ADRB2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.00227	0.00362	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00223	0.00355	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00221	0.00353	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.0022	0.0035	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.00205	0.00326	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00204	0.00325	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00204	0.00325	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00201	0.0032	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.002	0.00319	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00199	0.00318	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00196	0.00312	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00196	0.00312	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00192	0.00305	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00192	0.00305	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.00191	0.00305	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.00191	0.00305	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00188	0.00299	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00188	0.00299	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00185	0.00295	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00184	0.00294	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00181	0.00289	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00177	0.00282	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00174	0.00277	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00174	0.00277	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00173	0.00276	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00173	0.00276	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.00173	0.00276	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.0017	0.00271	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.0017	0.00271	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00146	0.00232	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00144	0.00229	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00143	0.00227	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00141	0.00224	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00132	0.00211	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00132	0.0021	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00131	0.00209	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.0013	0.00208	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.0013	0.00207	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.0013	0.00206	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.00129	0.00205	CbGpPWpGaD
Arbutamine—ADRB3—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.00128	0.00204	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.00128	0.00203	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00121	0.00193	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00119	0.0019	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.00119	0.00189	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00118	0.00188	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.00117	0.00186	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.00116	0.00185	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00109	0.00174	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00107	0.0017	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00103	0.00164	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00103	0.00164	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.00101	0.0016	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.00101	0.0016	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000782	0.00125	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000771	0.00123	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000765	0.00122	CbGpPWpGaD
Arbutamine—ADRB1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000759	0.00121	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000754	0.0012	CbGpPWpGaD
Arbutamine—ADRB2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000743	0.00118	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000705	0.00112	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000689	0.0011	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000689	0.0011	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000686	0.00109	CbGpPWpGaD
Arbutamine—ADRB3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000683	0.00109	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000674	0.00107	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000407	0.000649	CbGpPWpGaD
Arbutamine—ADRB1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000405	0.000645	CbGpPWpGaD
Arbutamine—ADRB3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000403	0.000642	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000398	0.000635	CbGpPWpGaD
Arbutamine—ADRB2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000396	0.000631	CbGpPWpGaD
Arbutamine—ADRB1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000239	0.000381	CbGpPWpGaD
Arbutamine—ADRB2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000234	0.000373	CbGpPWpGaD
